Download Recommended Resources - Alberta Health Services

Alberta RSV Prevention Program
Recommended Resources
Position Statements
1. Canadian Pediatric Society. Preventing respiratory syncytial virus infections. Paediatr
Child Health 2011;16(8):488-90
2. Fetus and Newborn Committee. Palivizumab and Respiratory Syncytial Virus Immune
Globulin Intravenous for the Prophylaxis of Respiratory Syncytial Virus Infection in High
Risk Infants. Pediatr Child Health 1999; 4: 474-480.
3. Canadian Pediatric Society. Use of Palivizumab in Children with Congenital Heart
Disease. Pediatric Child Health 2003; 8: 631-633
Epidemiology of RSV
1. Law BJ, Carbonell-Estrany X. Epidemiology of Respiratory Syncytial Virus Disease. J Resp
Dis for Pediatricians 2000; 2(4A)
Impact of RSV
1. IM-pact-RSV Study Group. Palivizumab, a Humanized Respiratory Syncytial Virus
Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection
in High-Risk Infants. Pediatrics 1998; 102: 531-537.
2. Abadesso C, Virella AD, Carreiro MH, Machado ME. Use of Palivizumab to Control an
Outbreak of Syncytial Respiratory Virus in a Neonatal Intensive Care Unit. Journal of
Hospital Infection 2004; 58: 38-41.
3. Oh PI, Lanctijt KL, Yoon A, et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus in
Canada: Utilization and Outcomes. Pediatric Infection Disease Journal 2002; 21: 512-518.
4. Sorrentino M, Powers T, Palivizumab Outcomes Study Group. Effectiveness of
Palivizumab: Evaluation of Outcomes from the 1998 to 1999 Respiratory Syncytial Virus
Season. Pediatric Infectious Disease Journal 2000; 19: 1068-71.
5. Simoes EAF, Groothuis JR, Carbonelle-Estrany X, Reiger CHL, Mitchell I, Fredrick LM, et al.
Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing:
Journal of Pediatrics 2007; 151: 34-42.
6. Banerji A, Greenberg d, White LF, MacDonald AW, Saxton A, Thomas E, et al. Risk Factors
and Viruses Associated With Hospitalization Due to Lower Respiratory Tract Infections in
Canadian Inuit Children: A Case-Control Study. Pediatric Infectious Disease Journal 2009;
28: 1-5.
7. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a "real life"
experience of respiratory syncytial virus infection prevention in infancy with and without
palivizumab. Pediatr Pulmonol 2006; 41(12):1167-74.
Congenital Heart Disease
1. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab Prophylaxis Reduces Hospitalization
due to Respiratory Syncytial Virus in Young Children with Hemodynamically Significant
Congenital Heart. J Pediatr 2003; 143: 532-40.
2. Apichia et al., Impact of Respiratory Syncytial Virus Infection on Surgery for Congenital
Heart Disease: Postoperative Causes and Outcomes. Critical Care Medicine 1999; 27:
33-35 Weeks Gestation
1. Carbonell-Estrany X, Figueras-Aloy J, IRIS Study Group. Identifying Risk Factors for Severe
Respiratory Syncytial Virus Among Infants Born After 33 Through 35 Completed Weeks of
Gestation. Pediatric Infectious Disease Journal 2004; 23: S193-201.
2. Law BJ, Langley JM, Allen U, Paes B, Lee DSC, Mitchell I, Sampalis J. The Pediatric
Investigators Collaborative Network on Infections in Canada Study of Predictors of
Hospitalization for Respiratory Syncytial Virus Infection for Infants Born 33 through 35
Completed Weeks Gestation. Pediatric Infectious Disease Journal 2004; 23: 806-814.
3. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-Control Study of the Risk Factors
Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature
Infants Born at a Gestational Age of 33-35 Weeks in Spain. Pediatric infectious Disease
Journal 2004; 9: 815-820.
Downs Syndrome
1. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a
novel risk factor for respiratory syncytial virus bronchiolitis–a prospective
birth-cohort study. Pediatrics. 2007; 120: e1076–e1081.
Second Season Prophylaxis
1. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. Evaluation of the Safety of
Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe
Respiratory Syncytial Virus Infection: Drug Safety 2003; 26: 283-91.
Cost Effectiveness of Prophylaxis
1. Nuijten MJC, Wittenberg W, Lebmeier M. Cost Effectiveness of Palivizumab for Respiratory
Syncytial Virus Prophylaxis in High-Risk Children. Pharmacoeconomics 2007; 25: 55-71.
To access additional articles,
follow the Canadian Association of Neonatal Nurses (CANN) website link –
http://www.neonatalcann.ca/
click on the “Respiratory Syncytial Virus (RSV) Information” found on the
right hand side of the home page.